Is Erasca, Inc. (ERAS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.1% / 30% | 6.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.1% / 33% | 6.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 10.3% / 33% | 59.4% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.1% / 33% | 6.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 10.3% / 33% | 59.4% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -33.3% | |
| Return on Assets (ROA) | -18.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$95M |
| Free Cash Flow | -$105M |
| Total Debt | $47M |
| Debt-to-Equity | 14.5 |
| Current Ratio | 10.0 |
| Total Assets | $396M |
Price & Trading
| Last Close | $15.16 |
| 50-Day MA | $12.79 |
| 200-Day MA | $4.95 |
| Avg Volume | 6.3M |
| Beta | 1.2 |
|
52-Week Range
$1.01
| |
About Erasca, Inc. (ERAS)
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Erasca, Inc. (ERAS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Erasca, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Erasca, Inc.'s debt ratio?
Erasca, Inc.'s debt ratio is 1.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.3%.
What are Erasca, Inc.'s key financial metrics?
Erasca, Inc. has a market capitalization of $4.7B. Return on equity stands at -33.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.